Furthermore, KRAS mutation is a marker for pancreatic ductal adenocarcinoma (PDAC) and is associated with key aspects of its biology, such as inflammation, immune escape and metabolic alterations (82–85). Here, KRAS is linked to pancreatic ductal adenocarcinoma.